BioAge Labs (NASDAQ:BIOA) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded shares of BioAge Labs (NASDAQ:BIOA) from a strong sell rating to a sell rating in a report released on Sunday morning,Wall Street Zen reports.

Several other research firms have also recently weighed in on BIOA. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Needham & Company LLC lowered their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Roth Capital reissued a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a report on Wednesday, September 9th. Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Finally, BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of BioAge Labs in a report on Tuesday, September 8th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, BioAge Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Price Performance

Shares of NASDAQ BIOA opened at $8.49 on Friday. BioAge Labs has a twelve month low of $4.68 and a twelve month high of $25.95. The stock’s 50 day moving average price is $14.93 and its 200-day moving average price is $17.42. The company has a market capitalization of $389.69 million, a PE ratio of -3.57 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. The company had revenue of $2.45 million during the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. As a group, research analysts expect that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Trading of BioAge Labs

A number of large investors have recently bought and sold shares of BIOA. Legal & General Group Plc bought a new stake in shares of BioAge Labs in the second quarter valued at $84,000. Russell Investments Group Ltd. purchased a new stake in BioAge Labs in the 3rd quarter worth about $27,000. State of Wyoming purchased a new stake in BioAge Labs in the 2nd quarter worth about $154,000. The Manufacturers Life Insurance Company purchased a new stake in BioAge Labs in the 2nd quarter worth about $234,000. Finally, Bank of Nova Scotia bought a new stake in BioAge Labs in the 1st quarter valued at about $180,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.